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Abstract
Background:  In most recent large efficacy trials of barrier contraceptive methods, a high
proportion of participants withdrew before the intended end of follow-up. The objective of this
analysis was to explore characteristics of participants who failed to complete seven months of
planned participation in a trial of spermicide efficacy.
Methods: Trial participants were expected to use the assigned spermicide for contraception for
7 months or until pregnancy occurred. In bivariable and multivariable analyses, we assessed the
associations between failure to complete the trial and 17 pre-specified baseline characteristics. In
addition, among women who participated for at least 6 weeks, we evaluated the relationships
between failure to complete, various features of their first 6 weeks of experience with the
spermicide, and characteristics of the study centers and population.
Results: Of the 1514 participants in this analysis, 635 (42%) failed to complete the study for
reasons other than pregnancy. Women were significantly less likely to complete if they were
younger or unmarried, had intercourse at least 8 times per month, or were enrolled at a university
center or at a center that enrolled fewer than 4 participants per month. Noncompliance with study
procedures in the first 6 weeks was also associated with subsequent early withdrawal, but
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dissatisfaction with the spermicide was not. However, many participants without these risk factors
withdrew early.
Conclusions: Failure to complete is a major problem in barrier method trials that seriously
compromises the interpretation of results. Targeting retention efforts at women at high risk for
early withdrawal is not likely to address the problem sufficiently.
Background
Retention of participants has been a consistent problem
in clinical studies of barrier contraceptive methods. For
example, in six large studies of condoms, diaphragms, and
spermicides conducted in the past decade, more than 30%
of the participants failed for reasons other than pregnancy
to complete the intended six months or six menstrual
cycles of follow-up [1-6] Such high dropout rates seriously
compromise the interpretation of trial results.
Issues regarding the design of barrier method studies have
become increasingly important to researchers and public
health scientists since the onset of the HIV epidemic
because of the urgent need for methods to prevent this
disease and other sexually transmitted infections. Numer-
ous new barrier contraceptive methods and microbicides
are currently in various stages of development and testing.
Devising effective approaches to maximize retention in
these studies will be critical.
In this analysis, we used data from a large, recently com-
pleted randomized trial of the efficacy and safety of five
spermicide products to determine whether we could iden-
tify specific subgroups of participants who were at partic-
ular risk for failure to complete the trial. Our goal was to
provide information that might assist in the development
of targeted approaches to improve follow-up in future
trials.
Methods
The primary purpose of this randomized trial was to esti-
mate and compare the probability of pregnancy during six
months of typical use of five nonoxynol-9 spermicide
products. Safety, acceptability, and product use were addi-
tional specified outcomes. The trial was conducted at 14
sites in the United States between June 1998 and August
2002. The study was approved by the institutional review
boards at each site and at Family Health International. All
participants signed written informed consent forms
before enrollment.
A full description of the trial procedures has been pub-
lished previously [7]. In brief, the study enrolled 1536
healthy, sexually active women aged 18–40 years who had
no history suggestive of subfecundity, who were at low
risk for sexually transmitted infections, and who stated
that they were willing to rely on a spermicide as their only
contraceptive method for 7 months and to accept a mod-
erate risk of pregnancy. At the enrollment visit, each vol-
unteer had an interview, pelvic examination, Pap smear,
wet prep, and urine pregnancy test. After eligibility was
established, she completed a self administered question-
naire that included a question about strength of desire to
avoid pregnancy. Each eligible participant was randomly
assigned to one of the five study spermicide groups. She
was given a supply of her assigned spermicide and a diary
on which to record relevant information daily throughout
the study. Some participants at two centers were enrolled
into a substudy to evaluate colposcopic effects of the sper-
micides. Participants were encouraged but not required to
inform their partners about the study except at one center,
where the Institutional Review Board required signed con-
sent of the partner.
Follow-up visits were scheduled at 4, 17, and 30 weeks
after admission. Each participant was also asked to return
to the study site if she wished to discontinue use of the
spermicide. At each visit, the participant was interviewed,
and a urine pregnancy test was done. At the 4-week and
final visits, she completed a seven-page acceptability ques-
tionnaire. A pelvic examination was performed at the final
visit and at other visits as indicated. Colposcopy substudy
participants had a vaginal colposcopy at each follow-up
visit. Each participant was asked to do a pregnancy test at
home 2, 10, and 23 weeks after admission and to tele-
phone the site with the result. If a participant missed a
scheduled contact, study procedures required that staff
make at least four attempts to contact her by at least two
different modalities (telephone, mail, etc.) If they could
not contact her directly, staff were to try to reach her
through an alternate contact person identified by the par-
ticipant at admission. Compensation for completion of
all scheduled visits in the primary study ranged from $120
to $400 at the 14 study sites; at most sites, the amount was
divided evenly among the separate visits.
In this analysis, we included all randomized participants
except for 22 who were discovered to have been pregnant
at admission and who therefore contributed no data to
the primary analysis. We classified each of the remaining
1514 participants as having completed the study if she
considered the spermicide to be her primary contraceptive
method for at least 183 days after randomization, or she
became pregnant before she stopped relying on it.BMC Medical Research Methodology 2004, 4:23 http://www.biomedcentral.com/1471-2288/4/23
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Otherwise, she was classified as having failed to complete
the study. We assigned each participant's last day in the
analysis as the earliest of the following dates: the esti-
mated date of fertilization of a pregnancy; the date she
was last known to have been relying primarily on the
assigned spermicide for contraception; the latest date her
pregnancy status could be reliably determined; and 183
days after randomization. These rules were the same as
those used in the prior primary pregnancy analyses [7].
We assessed the associations between failure to complete
and 17 baseline factors of interest, which were prespeci-
fied before the analysis. Among the subset of participants
who were in the analysis for at least 6 weeks, we examined
the associations between final status category and various
factors that characterized their experience during the first
6 weeks in the study. Factors were categorized in part to
ensure substantial numbers of participants in each level.
Hypotheses about the effects of factors on completion sta-
tus were tested using chi square tests, Fisher's exact tests,
Mantel Haenszel tests. Parameters estimated by multivar-
iable logistic regressions were tested using Wald tests. We
included factors in regression models if they were associ-
ated with the outcome (alpha<0.10) in bivariable analy-
ses. None of the included factors were highly correlated.
In both bivariable and multivariable analyses, a p-value of
<0.05 was considered to indicate a significant association.
Results
Of the 1514 participants in this analysis, 635 (42%) failed
to complete the study for reasons other than pregnancy.
The proportion who withdrew early at each of the 14
study sites ranged from 17% to 83%. Only 3 centers had
completion rates ≥65%. Forty nine participants (8% of
those who withdrew) were discontinued by the site inves-
tigator because of a concern about their safety (such as
increased risk of sexually transmitted infection that would
indicate need for condom use, or use of a drug contrain-
dicated in pregnancy that would indicate need for a more
effective contraceptive than spermicide alone), staff error,
or closure of the trial at the study site (Table 1). Of the 586
who withdrew on their own accord, 382 (65%) did not
provide a reason, in most cases because they did not
return for a discontinuation visit. The other 204 women
reported a variety of reasons; 99 cited complaints that
might have been related in some way to the spermicide.
Of the other 105 participants, only 31 said that they
would like to continue using the spermicide after leaving
the study.
During their time in the analysis, women who failed to
complete the study were less compliant with follow-up
visits and diary records than women who completed
(Table 2). Twenty-one percent of the population (135 par-
ticipants) contributed no data at all to the analysis after
admission.
Table 1: Reasons for early withdrawal
Reason Participants N = 635
n%
Discontinued by site
Safety concerns 38 6%
Site closure/staff error 11 2%
Participant decision, reason provided* 204 32%
Unwillingness to continue study visits 60 9%
Objections from partner† 48 8%
Desire to change contraceptive method† 42 7%
Separation from partner 40 6%
Side effects or other medical events† 37 6%
Cessation of sexual activity 18 3%
Dissatisfaction with spermicide† 81 %
Distrusted contraceptive efficacy† 81 %
Desire for pregnancy 7 1%
Mistaken suspicion of pregnancy 4 1%
Participant decision, reason unknown 382 60%
*Participants may have provided more than one reason
†Considered "related to spermicide" in text
Table 2: Protocol compliance by final status category
Final status category p-value†
Completed study Did not complete study
Number of participants 879 (58%) 635 (42%)
Median days in analysis per participant 183 32
Mean % of expected follow-up visits completed* 85% 64% <.0001
Mean % of expected diary days recorded* 97% 72% <.0001
Mean % of expected pregnancy tests completed* 95% 97% 0.0001
*The number of expected visits was prorated for each participant considering the total duration of her participation in the analysis
†p-value from independent sample t-test.BMC Medical Research Methodology 2004, 4:23 http://www.biomedcentral.com/1471-2288/4/23
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Of the 17 baseline factors examined separately, nine were
associated with significantly increased (p < 0.05) relative
risk of failure to complete the trial (Table 3). Factors that
did not significantly increase risk included spermicide
group, race, educational level, prior spermicide use,
strength of desire to avoid pregnancy as reported on the
self-administered admission questionnaire, desire for
additional children, reason for choosing spermicide as a
contraceptive method, and enrollment date relative to
notification in 1999 of new data suggesting concern about
the possibility that nonoxynol-9 might affect the risk of
HIV acquisition. In multivariable analyses including the
nine high risk factors and one additional factor (level of
schooling, which was marginally associated with with-
drawal, p = 0.09), only the associations with young age,
unmarried status, frequent intercourse, enrollment at a
university center, and enrollment at a center with a lower
recruitment rate remained significant.
Of the 1095 participants who contributed more than 6
weeks to the analysis, those who in their first 6 weeks were
not compliant with follow-up visits, coital diary comple-
tion, or use of the spermicide during sex were significantly
less likely than others to complete the study (Table 4).
However, among the 925 participants who completed a
contact during the initial 6 weeks, neither reported com-
plaints nor any measure of satisfaction with the spermi-
cide during the first 6 weeks was associated with increased
risk of early withdrawal. We created a single variable to
indicate whether or not each subject was "happy" with the
Table 3: Association between baseline factors and failure to complete study
Total Did not complete study Relative Risk (95% 
confidence interval)
Nn%
Age
≤25 years 660 317 48.0 1.29 (1.15 – 1.45)
> 25 years 854 318 37.2 1
Relationship
single not living with partner 522 247 47.3 1.21 (1.07 – 1.36)
married or living with partner 992 388 39.1 1
Living children
None 639 288 45.1 1.14 (1.0 1 – 1.28)
Any 875 347 39.7 1
Baseline coital frequency
≥8 acts per month 862 389 45.1 1.21 (1.07 – 1.37)
≤7 acts per month 640 239 37.3 1
Geographic region of US
West 424 215 50.7 1.28 (1.12 – 1.46)
South 460 170 37.0 0.93 (0.80 – 1.09)
Northeast 630 250 39.7 1
Center type
university* 1069 476 44.5 1.25 (1.08 – 1.44)
other 445 159 35.7 1
Recruitment rate at study site
≤4 per month 640 301 47.0 1.23 (1.09 – 1.38)
> 4 per month 874 334 38.2 1
Reimbursement rate
≤$200 462 232 50.2 1.31 (1.16 – 1.47)
>$200 1052 403 38.3 1
Participation in colposcopy study
No 1381 590 42.7 1.26 (0.99, 1.61)†
Yes 133 45 33.8 1
*University centers were defined as those at which participants were seen in a primary university clinic setting. These included: University of 
Alabama at Birmingham, Birmingham, AL; University of Tennessee at Memphis, Memphis, TN; The University of Texas Health Science Center at San 
Antonio, San Antonio, TX; Baylor College of Medicine, Houston, TX; Medical University of South Carolina, Charleston, SC; University of Pittsburgh 
and the Magee-Womens Research Institute, Pittsburgh, PA; University of Pennsylvania Medical Center, Philadelphia, PA; University of Arizona 
Health Sciences Center, Tucson, AZ; NYU School of Medicine, New York, NY. Other centers included: Johns Hopkins Medical Services 
Corporation, Baltimore, MD; Vermont Women's Choice Program of Planned Parenthood, Burlington, VT; Eastern Virginia Medical School, Norfolk, 
VA; Minneapolis Medical Research Foundation, Minneapolis, MN; Planned Parenthood of Central and Northern Arizona, Phoenix, AZ
†Although this confidence limit includes 1, the p-value for the association between this factor and early withdrawal was 0.047.BMC Medical Research Methodology 2004, 4:23 http://www.biomedcentral.com/1471-2288/4/23
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spermicide in the first 6 weeks after admission (i.e., she
found it acceptable, had no side effect or adverse event,
and had a satisfied partner). Women who were "happy"
were not significantly less likely than other women to
withdraw early.
Discussion and conclusions
In analyzing data from longitudinal studies, researchers
commonly assume that the experience of participants
who withdraw early, had they stayed in the study, would
have been similar to the experience of those who com-
pleted. However, this assumption is generally impossible
to confirm and is often implausible. If the assumption is
false, the study findings may substantially misrepresent
the likelihood of the outcome in the study population. If
the degree of misrepresentation is not consistent across
study groups, comparisons could be seriously biased.
Indeed, some expert epidemiologists have suggested that
a trial with losses of greater than 20% of the participants
Table 4: Association between early study experience and failure to complete study*
Experience during first 6 weeks Total Did not complete study Relative Risk (95% 
confidence interval)
Nn%
Completed at least one follow-up visit
yes 925 203 21.9 0.68 (0.53 – 0.87)
no 170 55 32.4 1
Completed at least one pregnancy test 
within first 4 weeks
yes 1070 250 23.4 0.73 (0.41 – 1.31)
no 25 8 32.0 1
Provided diary information for each day
yes 958 215 22.4 0.71 (0.54 – 0.94)
no 137 43 31.4 1
Used spermicide at every coital act
yes 739 153 20.7 0.70 (0.57 – 0.87)
no 356 105 29.5 1
Of those who completed follow-up visit
Reported medical complaints
yes 437 104 23.8 1.17 (0.92 – 1.50)
no 488 99 20.3 1
Disliked spermicide somewhat or a 
lot
yes 52 12 23.1 1.05 (0.63 – 1.76)
no 873 191 21.9 1
Distrusted contraceptive efficacy
yes 209 51 24.4 1.15 (0.87 – 1.52)
no 716 152 21.2 1
Disliked timing of application
yes 435 96 22.1 1.01 (0.79 – 1.29)
no 490 107 21.8 1
Complained about messiness
yes 375 76 20.3 0.88 (0.68 – 1.13)
no 550 127 23.1 1
Had problems with insertion
yes 465 105 22.6 1.06 (0.83 – 1.35)
no 460 98 21.3 1
Reported that partner disliked 
spermicide
yes 208 52 25.0 1.18 (0.90 – 1.56)
no 717 151 21.1 1
Happy with spermicide†
yes 408 80 19.6 0.82 (0.64 – 1.05)
no 517 123 23.8 1
*Includes only participants in the analysis for at least 6 weeks
†Did not dislike spermicide, had no side effect/AE, and had a satisfied partnerBMC Medical Research Methodology 2004, 4:23 http://www.biomedcentral.com/1471-2288/4/23
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"would be unlikely to successfully withstand challenges to
its validity" [8,9].
Our study, like other recent barrier contraceptive method
studies, did not even approach this standard: 42% of our
enrolled participants did not complete the trial. Further-
more, the participants who failed to complete were differ-
ent in key ways from those who did – they reported
significantly more frequent coitus at baseline, and they
also were more likely to be younger, unmarried, and
poorly compliant with study procedures and method use
in the first few weeks after admission. All of these charac-
teristics were associated to some extent with elevated risk
of pregnancy in our population [7], which suggests that
our high withdrawal rate indeed may have distorted our
findings: the pregnancy probabilities that we reported
may be underestimates.
Clearly, increased attention to preventing this problem in
future studies is imperative. In performing this analysis,
our intention was to explore the potential impact of focus-
ing retention efforts on participants with characteristics
that are associated with failure to complete. However,
although we did find some factors that were significantly
associated with early withdrawal, none was highly predic-
tive; that is, many participants without these factors failed
to complete the study, and many with these factors did
complete. Therefore, applying special efforts only to the
high-risk participants would not likely have been
sufficient to raise completion rates to desirable levels. In
future trials, aggressive follow-up measures should be
instituted universally. Such efforts might include assign-
ing individual "case-workers" to participants, using novel
means for communicating with the participants, such as
pagers, conducting visits at participants' homes or at other
locations convenient for them, providing specific reim-
bursement for expenses such as travel, parking, and child
care, or providing extra incentives for completing follow-
up. Researchers should be mindful, however, that one
downside to some of these approaches is that they might
influence participants' use of the study product or other
behaviors related to the study outcome, which is detri-
mental if the goal of the trial is to estimate effectiveness
during "typical use" of the product.
In our study, participants who enrolled at study centers
where enrollment was slow were at increased risk of fail-
ure to complete the study. The reason for this association
is unclear. Factors at these centers that hindered enroll-
ment also may have adversely affected participants' inter-
est in remaining in the study. Alternatively, in responding
to pressure to hasten recruitment, these centers may have
enrolled women who were not good candidates for study
completion. This latter possibility emphasizes the need to
maintain a careful balance between recruitment and
retention goals: rapid recruitment of participants who
then drop out of the study is not beneficial to the study as
a whole.
The amount of reimbursement promised to our partici-
pants was strongly associated with final completion status
in the bivariable analysis, but this effect was not signifi-
cant when adjusted for other factors in our multivariable
model. Numerous prior studies have shown that modest
monetary incentives (e.g., $20 or less) increase response
rates to surveys or short follow-up studies [10,11] Some
data also suggest that the value of the incentive matters,
although possibly with diminishing returns as the value
increases [12,13]. However, the effect of higher levels of
compensation in longer trials such as ours has not been
rigorously studied. The possibilities that large financial
incentives could be coercive, weaken generalizability, or
encourage bogus participation are important concerns
[14].
We were surprised that several of the factors that we
expected would be associated with early withdrawal did
not show significant associations in this analysis. When
we began this analysis, we presumed that one reason for
both slow enrollment and poor follow-up rates in barrier
method trials is the relatively poor efficacy of these prod-
ucts: women may consider them to be temporary or
backup methods and thus may be unwilling to use them
as their sole or primary contraceptive for the 6–12 month
duration of these studies. However, in our study, partici-
pants who strongly wished to avoid pregnancy or who
had completed their desired family size were not more
likely than others to drop out, nor were participants who
expressed concerns about contraceptive efficacy early in
the trial. Furthermore, neither early medical problems nor
other complaints about the spermicides were predictive of
withdrawal. These findings differ from that of a previous
randomized trial of spermicides conducted mostly in
developing countries. In that trial, participants who ini-
tially liked the assigned product very much were more
likely than others subsequently to complete the study and
to use the product for a longer period of time after admis-
sion [15].
In one respect, the poor retention rate in our study and in
other barrier method trials is a result of the design of these
studies, which typically call for censoring data (and in
most barrier method trials, terminating active follow-up)
when participants stop relying on the assigned contracep-
tive method. This design prohibits a true intent-to-treat
analysis and is consequently a potential source of bias.
Clearly, retention would be higher if the trials were
designed at the outset to follow all subjects for the full
intended duration of follow-up, even if they switched
contraceptive methods. However, data from participantsBMC Medical Research Methodology 2004, 4:23 http://www.biomedcentral.com/1471-2288/4/23
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who are not using the method under study are not neces-
sarily relevant to the efficacy and safety of the method. For
the results of these trials to be meaningful, as many sub-
jects as possible must not only complete follow-up but
also continue to use the method during the full follow-up
period. In our study, almost all the women who gave a
reason for withdrawing early either cited problems with
the spermicide or indicated that they wished to switch to
another method after leaving the study. Our results are
consistent with the findings of the 1995 National Survey
of Family Growth, which showed that more than 47% of
US spermicide users stopped relying on the method
within the first 6 months of use [16]. These findings are
discouraging: they suggest that even if the retention in the
study could be improved by aggressive follow-up tech-
niques, the likelihood of significant extension of method
use is low.
Our results suggest that to reduce bias potentially intro-
duced by a large proportion of participants failing to com-
plete the study, future barrier contraceptive method
researchers should consider approaches in addition to
those directly aimed at tracking and retaining individual
participants. For example, both to reduce the burden on
participants and to help the study staff maintain focus on
follow-up, limiting data collection to critical variables
may be appropriate. Complete collection of key data is
clearly preferable to inadequate collection of less impor-
tant data. Reducing the planned duration of follow-up
would also certainly reduce withdrawals; although a larger
sample size would be needed to provide the desired levels
of precision and power, this disadvantage might be over-
come if the shorter study were more attractive to potential
participants. Given the large proportion of women who
stop using the method earlier than 6 months, it is not clear
that 6-month pregnancy probabilities are clinically
needed anyway. Adding a run-in period to the trial before
randomization might be helpful in excluding participants
likely to drop out very early after admission, although
such an addition might deter enrollment of other women
as well, which is also a problem in these trials. Finally,
innovative study designs to measure product efficacy
should be evaluated. The design proposed by Steiner et al.,
which compares the one-month pregnancy probability in
a relatively small number of women using a contraceptive
method to the probability in women using a placebo,
offers an alternative to the traditional 6–12 month trial
[17]. It showed some promise in a pilot study and is cur-
rently being further tested in a study of a new candidate
spermicide.
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